$36.45
0.27% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US85205L1070
Symbol
SWTX
Sector
Industry

SpringWorks Therapeutics Inc Target price 2024 - Analyst rating & recommendation

SpringWorks Therapeutics Inc Classifications & Recommendation:

Buy
100%

SpringWorks Therapeutics Inc Price Target

Target Price $68.00
Price $36.45
Potential
Number of Estimates 8
8 Analysts have issued a price target SpringWorks Therapeutics Inc 2025 . The average SpringWorks Therapeutics Inc target price is $68.00. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 8 analysts: 8 Analysts recommend SpringWorks Therapeutics Inc to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the SpringWorks Therapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the SpringWorks Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 5.45 192.21
3,426.84%
EBITDA Margin -6,263.30% -127.40%
97.97%
Net Margin -7,024.79% -120.72%
98.28%

7 Analysts have issued a sales forecast SpringWorks Therapeutics Inc 2024 . The average SpringWorks Therapeutics Inc sales estimate is

$192m
Unlock
. This is
41.86% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$197m 45.25%
Unlock
, the lowest is
$187m 38.09%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $5.5m
2024
$192m 3,426.84%
Unlock
2025
$374m 94.66%
Unlock
2026
$605m 61.73%
Unlock
2027
$1.1b 84.18%
Unlock

3 Analysts have issued an SpringWorks Therapeutics Inc EBITDA forecast 2024. The average SpringWorks Therapeutics Inc EBITDA estimate is

$-245m
Unlock
. This is
16.21% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-244m 16.51%
Unlock
, the lowest is
$-245m 16.01%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-341m 22.44%
2024
$-245m 28.26%
Unlock
2025
$-112m 54.17%
Unlock
2026
$-128m 14.07%
Unlock

EBITDA Margin

2023 -6,263.30%
2024
-127.40% 97.97%
Unlock
2025
-30.00% 76.45%
Unlock
2026
-21.16% 29.47%
Unlock

7 SpringWorks Therapeutics Inc Analysts have issued a net profit forecast 2024. The average SpringWorks Therapeutics Inc net profit estimate is

$-232m
Unlock
. This is
16.31% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-222m 19.84%
Unlock
, the lowest is
$-239m 13.67%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-383m 1.15%
2024
$-232m 39.39%
Unlock
2025
$-133m 42.70%
Unlock
2026
$-42.1m 68.31%
Unlock
2027
$258m 712.30%
Unlock

Net Margin

2023 -7,024.79%
2024
-120.72% 98.28%
Unlock
2025
-35.54% 70.56%
Unlock
2026
-6.96% 80.42%
Unlock
2027
23.15% 432.61%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2027

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -5.15 -3.12
1.15% 39.42%
P/E negative
EV/Sales 12.18

7 Analysts have issued a SpringWorks Therapeutics Inc forecast for earnings per share. The average SpringWorks Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-3.12
Unlock
. This is
16.35% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-2.99 19.84%
Unlock
, the lowest is
$-3.22 13.67%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-5.15 1.15%
2024
$-3.12 39.42%
Unlock
2025
$-1.79 42.63%
Unlock
2026
$-0.57 68.16%
Unlock
2027
$3.47 708.77%
Unlock

P/E ratio

Current -9.78 152.06%
2024
-11.68 19.43%
Unlock
2025
-20.38 74.49%
Unlock
2026
-64.32 215.60%
Unlock
2027
10.50 116.32%
Unlock

Based on analysts' sales estimates for 2024, the SpringWorks Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

12.18
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
14.11
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 17.28
2024
12.18 29.50%
Unlock
2025
6.26 48.63%
Unlock
2026
3.87 38.17%
Unlock
2027
2.10 45.71%
Unlock

P/S ratio

Current
2024
14.11 29.51%
Unlock
2025
7.25 48.63%
Unlock
2026
4.48 38.17%
Unlock
2027
2.43 45.71%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today